Navigation Links
Omeros Commences Initial Public Offering of Common Stock
Date:9/18/2009

SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Omeros Corporation today announced the launch of its initial public offering of 6.82 million shares of its common stock. Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.

The estimated price range for the initial public offering is $10.00 to $12.00 per share. Omeros has applied to have the shares of common stock listed on The NASDAQ Global Market under the ticker symbol "OMER." The underwriters have the option to purchase up to an additional 1.02 million shares to cover over-allotments, if any. All of the shares of common stock will be offered by Omeros.

Omeros intends to use the net proceeds of the offering to fund the completion of its Phase 3 clinical trials of OMS103HP, its lead product candidate being evaluated for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain, as well as the potential launch and commercialization of OMS103HP. The Company also intends to use the net proceeds to fund the development of its other product candidates in the clinic, OMS302 for ophthalmology and OMS201 for urology, and the development of its pipeline of preclinical programs.

Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Wedbush PacGrow Life Sciences will be acting as the co-lead manager, Canaccord Adams Inc. and Needham & Company, LLC will be acting as co-managers, and Chicago Investment Group, LLC and National Securities Corporation will be acting as junior co-managers. The offering will be made only by means of a prospectus.

Copies of the preliminary prospectus may be obtained by contacting: Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telepho
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
2. Omeros Appoints New Vice President of Clinical Development
3. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros and BlueCrest Announce $20 Million Debt Facility
6. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
7. Omeros Appoints David A. Mann to its Board of Directors
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
11. PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a ... appointment of Dr. Roger J Garceau, to its ... companies in matters including corporate development and clinical ... adds significant regulatory expertise as Fluorinov transitions to ... 30 years of pharmaceutical development experience to Fluorinov ...
(Date:5/4/2015)... 04, 2015 Genedata, a leading ... and life science research, today announced the release ... version of its enterprise solution for biologics R&D. ... more efficient discovery and development of novel biotherapeutics. ... and address protein optimization and developability requirements. Genedata ...
(Date:5/4/2015)... 4, 2015 China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has been ... Hong Kong listed company and ... an agreement (the "Agreement") to purchase the Company,s outstanding ...
(Date:5/4/2015)... , May 4, 2015   Intrexon Corporation ... first quarter 2015 financial results after the market closes ... conference call that day at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Conference Call."  Participants may also ...
Breaking Biology Technology:Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2
... March 2 BioMed Realty Trust, Inc. (NYSE: ... executive management will present at the Citi 2009 Global ... a.m. Eastern Standard Time on Wednesday, March 4, 2009.The ... 719.785.5595 and providing the passcode 348395. About BioMed Realty ...
... March 2 Gen-Probe Incorporated (Nasdaq: GPRO ... under a newly issued line of credit to finance ... other general corporate activities, including its existing share repurchase ... million revolving credit facility, provided by Bank of America, ...
... Innovative B.C. Technology Promises to Revolutionize Food Processing, ... EnWave Corporation (TSX-V: ENW) ("EnWave" or "the Company") ... sale of its continuous nutraREV(TM) food dehydration equipment ... one of B.C.,s largest blueberry producers. With this ...
Cached Biology Technology:Gen-Probe Borrows $170 Million Under New Line of Credit 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... 16 Researchers at the University of Pittsburgh School ... of women with major depressive disorder that link two ... illness. Their results, published online this week in Molecular ... a mouse model that could enhance future research on ...
... PORTLAND, Ore. New research in mice indicates that ... and during pregnancy have a higher fat mass and smaller ... scientists at Oregon Health & Science University Doernbecher Children,s Hospital. ... moms who switch to a low-fat diet during pregnancy considerably ...
... over the biosecurity of the Galpagos Islands is needed, ... West Nile virus., Scientists from the Zoological Society of ... York State Department of Health, together with the Galpagos ... studying the disease threat posed by Islands, mosquito populations. ...
Cached Biology News:Pitt team finds molecular evidence of brain changes in depressed females 2Moms who eat high-fat diet before, during pregnancy 'program' babies to be fat, at risk 2New threat closes in on iconic Galápagos wildlife 2
in vitro Translation, Accessory Products...
Request Info...
... host strains are K-12 derivatives that have ... and glutathione reductase (gor) genes, which greatly ... Studies have shown that expression in Origami(DE3) ... another host even though overall expression levels ...
Request Info...
Biology Products: